Edition:
India

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

13.60USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$13.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,858
52-wk High
$29.00
52-wk Low
$11.90

Select another date:

Mon, Feb 5 2018

BRIEF-Paratek Completes Submission Of New Drug Applications To U.S.FDA

* PARATEK COMPLETES SUBMISSION OF NEW DRUG APPLICATIONS TO U.S. FOOD AND DRUG ADMINISTRATION FOR ORAL AND INTRAVENOUS OMADACYCLINE FOR PNEUMONIA AND SKIN INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Paratek Announces $50.0 Mln Public Offering Of Common Stock

* PARATEK PHARMACEUTICALS INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS SHARES OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Paratek Provides Update On Pipeline Progress

* PARATEK PHARMACEUTICALS - HAS EARNED A $5 MILLION MILESTONE PAYMENT FROM ALLERGAN FOR DEVELOPMENT OF SEYSARA Source text for Eikon: Further company coverage:

BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln

* PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​ Source text (http://bit.ly/2BqNSiB) Further company coverage:

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018

BRIEF-Paratek Pharmaceuticals to report Q3 results on Nov 8

* Paratek Pharmaceuticals to report third quarter 2017 financial results and provide update on clinical progress on November 8, 2017 Source text for Eikon: Further company coverage:

BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline

* Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline in patients with difficult to treat comorbid conditions

BRIEF-Paratek Pharma antibiotic granted additional qualified infectious disease product designation by FDA​

* Paratek Pharmaceuticals Inc - its antibiotic omadacycline has been granted additional qualified infectious disease product designation by U.S. FDA​ Source text for Eikon: Further company coverage:

Select another date: